Primary Site >> Colorectal Cancer
Gene >> ROS1
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|
|
Ref: Degree of tumour vascularity correlates with drug accumulation and tumour response upon TNF-alpha-based isolated hepatic perfusion. PMID: 12610519 |
Ref: Identification of ROS1 rearrangement in gastric adenocarcinoma. PMID: 23400546 Ref: Breakpoint analysis of transcriptional and genomic profiles uncovers novel gene fusions spanning multiple human cancer types. PMID: 23637631 Ref: Molecular pathways: ROS1 fusion proteins in cancer. PMID: 23719267 |
Ref: ROS1 and ALK fusions in colorectal cancer, with evidence of intratumoral heterogeneity for molecular drivers. PMID: 24296758 Ref: Predictive molecular markers in metastases to the central nervous system: recent advances and future avenues. PMID: 25287912 Ref: Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type. PMID: 25392179 |
Ref: ALK and ROS1 overexpression is very rare in colorectal adenocarcinoma. PMID: 24992173 Ref: Systematic search for rare variants in Finnish early-onset colorectal cancer patients. PMID: 25749350 Ref: A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance. PMID: 26358176 Ref: Entrectinib: a potent new TRK, ROS1, and ALK inhibitor. PMID: 26457764 Ref: Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer. PMID: 26633560 |
Ref: ROS1 Kinase Inhibitors for Molecular-Targeted Therapies. PMID: 26438251 Ref: Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications. PMID: 26939704 |
Ref: Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1). PMID: 28183697 Ref: ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers. PMID: 28465216 Ref: Identification and characterization of a novel SCYL3-NTRK1 rearrangement in a colorectal cancer patient. PMID: 28903424 Ref: ROS1-1. PMID: 28903995 Ref: ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer. PMID: 29370427 |
Ref: Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): A phase 1b open-label study. PMID: 29352732 Ref: Germline mutations in candidate predisposition genes in individuals with cutaneous melanoma and at least two independent additional primary cancers. PMID: 29641532 Ref: Next-generation sequencing analysis of receptor-type tyrosine kinase genes in surgically resected colon cancer: identification of gain-of-function mutations in the RET proto-oncogene. PMID: 29665843 |